tyrosine kinase
Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice
... Tyrosine kinase inhibitors (TKIs) changed the treat- ment and survival of patients with chronic myeloid leukemia (CML) radically and are currently the cornerstone of CML treatment, improving outcomes and ...
8
Prevalence of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD+) in de novo acute myeloid leukemia patients categorized according to cytogenetic risk
... FMS-like tyrosine kinase 3/inter- nal tandem duplication (FLT3/ITD+), a class I mutation, in providing a myeloproliferative signal and/or survival advantage to leukemia cells, this mutation does not affect ...
5
Pancytopenia during tyrosine kinase inhibitor treatment–coexistence of chronic myeloid leukemia and visceral leishmaniasis : a case report
... tive tyrosine kinase activity [1–7]. Tyrosine kinase inhib- itors (TKIs) such as imatinib are able to suppress the BCR-ABL+ clone and induce molecular remission ...
4
Insulin receptor has tyrosine kinase activity toward Shc in rat liver
... of tyrosine kinase activity is essential for most intracel- lular signaling pathways ...the tyrosine kinase capacity of their own receptors, lead to the transfer of phosphate groups of ATP to ...
6
Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.
... receptor tyrosine kinase), mTOR/AKT (target of rapamycin/AKT), or ERK1,2 (extracellular-signal-regulated ki- nase), all implicated in AR phosphorylation ...
10
Directed Evolution of a Highly Specific FN3 Monobody to the SH3 Domain of Human Lyn Tyrosine Kinase.
... The kinase assay was performed with a Beacon Tyrosine kinase assay kit (Invitrogen, A- 35725) according to the manufacturer’s ...The kinase buffer was prepared by sup- plementing the provided ...
22
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
... intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor ...other tyrosine and serine/threonine ...other tyrosine kinase inhibitors; indeed, masitinib-induced ...
12
Involvement of Src tyrosine kinase and protein kinase C in the expression of macrophage migration inhibitory factor
... H 2 O 2 -induced MIF production was completely inhibited by tyrosine kinase inhibitors genistein and PP1, as well as by protein kinase C (PKC) inhibitor GF109203X, suggesting that redox-[r] ...
6
Structural basis for the regulation mechanism of the tyrosine kinase CapB from Staphylococcus aureus.
... of tyrosine-phosphorylating enzymes. However, several tyrosine kinases without similarity to their eukaryotic counterparts have recently been identified in ...bacterial tyrosine kinases can thus be ...
11
An update on anticancer triazene compounds
... EGFR tyrosine kinase that belong to the quinazoline class act by competitively binding to its ATP binding site, thereby blocking subsequent activation of downstream signalling cascades, including ...
66
Recent advances in angiotensin II signaling
... intracellular tyrosine kinases that play a role in growth signaling and inflammation, such as Src, Pyk2, p130Cas, FAK and ...of tyrosine kinase receptors, including PDGFR, EGFR and ...
15
Clinics vol.70 número8
... second tyrosine kinase ...third tyrosine kinase inhibitor were not sustainable, a third tyrosine kinase inhibitor may be an option for improving patient status until a donor ...
6
Rev. Assoc. Med. Bras. vol.59 número3 en v59n3a06
... Despite the correlation between qPCR and cytogenetic analy- sis, other prognostic factors may be associated with molecular or cytogenetic responses, affecting the outcomes during tyrosine kinase inhibitors ...
13
Clinics vol.68 número10
... encodes focal adhesion kinase (FAK), a tyrosine kinase involved in cell proliferation, adhesion and migration (3). FAK is overexpressed in several cancers and its expression usually correlates with a ...
5
Estrogenic Regulation of the SCF/c-KIT System in Prostate Cells: a Relationship with Prostate Cancer?
... The tyrosine kinase receptor c-KIT and its ligand, the Stem Cell Factor (SCF) are powerful agents stimulating cell proliferation in a broad range of tissues, and the SCF/c-KIT interaction seems to play a ...
110
Rev. Bras. Hematol. Hemoter. vol.39 número3
... with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing ...
2
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
... USA. Tyrosine kinase inhibitors: Erlotinib Hydrochloride Salt, gefitinib Free Base, Vandetanib Free Base Lapatinib, Imatinib and Paclitaxel were from LC Laboratories, USA; SU11274, PHA-665752 hydrate and ...
22
Rev. Bras. Hematol. Hemoter. vol.34 número5
... Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis amo[r] ...
16
Rev. Bras. Hematol. Hemoter. vol.36 número1
... Extraordinary scientific progress made in the field of chronic myeloid leukemia (CML) led to the development of orally available tyrosine kinase inhibitors (TKIs), dramatically improv[r] ...
6
Protein tyrosine kinases in Schistosoma mansoni
... SmRTK1 is a membrane protein with an extracellular binding domain similar to several protein domains that share the Venus Flytap-VFT structure and the cytoplas- matic TK domain, which is similar to the insulin receptor ...
8